Scarica l'app Stockscreener
7.43
0.13%
0.010
Dopo l'orario di chiusura:
7.47
0.04
+0.54%
Precedente Chiudi:
$7.42
Aprire:
$7.58
Volume 24 ore:
1.04M
Relative Volume:
0.63
Capitalizzazione di mercato:
$490.48M
Reddito:
$170.44M
Utile/perdita netta:
$-193.88M
Rapporto P/E:
-1.9792
EPS:
-3.7541
Flusso di cassa netto:
$-126.38M
1 W Prestazione:
+0.41%
1M Prestazione:
-22.60%
6M Prestazione:
-12.90%
1 anno Prestazione:
-29.77%
Intervallo 1D:
$7.36
$7.62
Intervallo di 1 settimana:
$7.1701
$7.86
Portata 52W:
$5.455
$16.19
Regenxbio Inc Stock (RGNX) Company Profile
Nome
Regenxbio Inc
Settore
Industria
Telefono
240-552-8181
Indirizzo
9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare RGNX vs VRTX, MRNA, REGN, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
7.43 | 488.50M | 170.44M | -193.88M | -126.38M | -3.7541 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2025-02-11 | Downgrade | Goldman | Buy → Neutral |
| 2025-02-07 | Ripresa | Raymond James | Outperform |
| 2024-11-15 | Ripresa | Morgan Stanley | Overweight |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-06-07 | Iniziato | Goldman | Buy |
| 2024-03-11 | Iniziato | H.C. Wainwright | Buy |
| 2024-03-08 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | Ripresa | Raymond James | Outperform |
| 2023-11-01 | Iniziato | Stifel | Buy |
| 2023-06-02 | Iniziato | Robert W. Baird | Outperform |
| 2022-06-23 | Iniziato | Berenberg | Buy |
| 2021-12-15 | Iniziato | Wedbush | Neutral |
| 2021-10-19 | Ripresa | Morgan Stanley | Overweight |
| 2021-01-06 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | Iniziato | UBS | Buy |
| 2020-06-25 | Ripresa | BofA/Merrill | Buy |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | Reiterato | Chardan Capital Markets | Buy |
| 2019-06-14 | Ripresa | Raymond James | Outperform |
| 2019-06-05 | Reiterato | Chardan Capital Markets | Buy |
| 2019-02-25 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-02-05 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | Reiterato | Chardan Capital Markets | Buy |
| 2018-11-08 | Reiterato | BofA/Merrill | Neutral |
| 2018-08-08 | Reiterato | Chardan Capital Markets | Buy |
| 2018-07-23 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | Reiterato | Chardan Capital Markets | Buy |
| 2018-05-09 | Reiterato | Barclays | Overweight |
| 2018-04-09 | Reiterato | Chardan Capital Markets | Buy |
| 2018-03-12 | Downgrade | Evercore ISI | Outperform → In-line |
| 2018-02-13 | Iniziato | Mizuho | Neutral |
| 2017-11-09 | Ripresa | Morgan Stanley | Overweight |
Mostra tutto
Regenxbio Inc Borsa (RGNX) Ultime notizie
ETFs Investing in REGENXBIO, Inc. Stocks - TradingView
Net income before discontinued operations of REGENXBIO, Inc. – HAN:RB0 - TradingView
H.C. Wainwright reiterates Regenxbio stock rating on diabetic retinopathy data - Investing.com
REGENXBIO Inc. (RGNX) stock price, news, quote and history - Yahoo Finance Singapore
REGENXBIO Inc. (RGNX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Why is Regenxbio stock climbing today? By Investing.com - Investing.com Australia
REGENXBIO reports three-year ALTITUDE DRSS data - Mugglehead Investment Magazine
REGENXBIO stock reports 60 percent three-year eye study response - AD HOC NEWS
Stifel reiterates Regenxbio stock rating on gene therapy data - Investing.com
Why is Regenxbio stock climbing today? - Investing.com
Regenxbio stock gains on positive gene therapy trial data - Investing.com
Regenxbio stock gains on positive gene therapy trial data By Investing.com - Investing.com Australia
REGENXBIO reports three-year sura-vec Phase II results - grafa.com
Stifel Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $42 - Moomoo
RGNX Looks 52.3% Undervalued on GF Value™ Despite Challenges - GuruFocus
REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting - PR Newswire
Sarepta Settles Regenxbio’s Patent Infringement Claims in $39M Deal - GenomeWeb
RGNX Stock Slumps 15% After-Hours — What’s Driving The Selloff? - Stocktwits
Sarepta to pay Regenxbio $39M to settle gene therapy claims; Vida eyes fourth fund - Endpoints News
REGENXBIO and Sarepta Resolve ELEVIDYS Patent Litigation with $39 Million Settlement - Kalkine Media
RGNX Stock: Clear Street Sees Potential Cash Risk From RGX-121 FDA Hold - Stocktwits
Regenxbio says Sarepta To Pay $39 Million To Regenxbio Within 10 Days Of Effective Date - TradingView
Responsive Playbooks and the RGNX Inflection - Stock Traders Daily
REGENXBIO stock edges lower as short interest stays elevated - AD HOC NEWS
Regenxbio Stock Price Forecast. Should You Buy RGNX? - StockInvest.us
REGENXBIO Inc. (RGNX) Stock Analysis: Exploring a Potential 188.83% Upside in Biotech Innovation - DirectorsTalk Interviews
REGENXBIO Inc. stock steadies after Morgan Stanley conference appearance - AD HOC NEWS
RGNX: Late-stage gene therapy programs advance toward commercialization, with strong efficacy and safety data - TradingView
RGNX: Late-stage gene therapy programs advance toward commercialization, with strong data and funding - TradingView
REGENXBIO at Morgan Stanley conference: late-stage gene therapy push - Investing.com
REGENXBIO at 2026 Global Healthcare Conference: pipeline, cash runway By Investing.com - Investing.com Nigeria
REGENXBIO at 2026 Global Healthcare Conference: pipeline, cash runway - Investing.com
Certain Warrants of REGENXBIO Inc. are subject to a Lock-Up Agreement Ending on 15-SEP-2026. - marketscreener.com
Avoiding Lag: Real-Time Signals in (RGNX) Movement - Stock Traders Daily
Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy - Stocktwits
Wet Age-Related Macular Degeneration Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | Opthea Limited, Regenxbio, Alkahest, Graybug Vision, Alcon Research - Barchart.com
REGENXBIO to present at two major healthcare investor conferences in September 2026 - Pluang
REGENXBIO to Participate in Upcoming Investor Conferences - marketscreener.com
This REGENXBIO Insider Increased Their Holding In The Last Year - 富途牛牛
QURE Or RGNX: Which Gene Therapy Was FDA Chief Really Warning About In Rare Disease Remarks? - Stocktwits
REGENXBIO Inc. (RGNX) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Regenxbio’s Gene Therapy Faces Another FDA Setback in Hunter Syndrome - Yahoo Finance
REGENXBIO CTO Malzahn Craig Retains 81,960 Shares After Forfeiture on September 1, 2026 - Kalkine Media
REGENXBIO CFO Chan Mitchell Forfeits 4,902 Shares at $9.32 Each (NASDAQ: RGNX) - Kalkine Media
REGENXBIO CFO Mitchell Chan Reports Tax-Driven Share Withholding on RSU Vesting - Kalkine Media
How Regenxbio Inc. (RGNX) Affects Rotational Strategy Timing - Stock Traders Daily
REGENXBIO Faces Clinical Hold on RGX-121 but Duchenne BLA Advances - streetwisereports.com
REGENXBIO (RGNX) Slips 1.86% to $9.48 as Gene Therapy Stock Presses Toward SupportTriangle Correction - careplusvn.com
REGENXBIO Faces FDA Clinical Hold on Hunter Syndrome Gene Therapy - Streetwise Reports
RGNX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
People on the Move: Greg Ciongoli Joins REGENXBIO’s Board of Directors - BioBuzz
Regenxbio Inc Azioni (RGNX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Regenxbio Inc Azioni (RGNX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Ciongoli Gregory Austin | Director |
Aug 26 '26 |
Buy |
9.14 |
49,196 |
449,706 |
64,628 |
| PAKOLA STEVE | Chief Medical Officer |
Jul 02 '26 |
Option Exercise |
7.86 |
2,161 |
16,985 |
215,170 |
| PAKOLA STEVE | Chief Medical Officer |
Jul 02 '26 |
Sale |
13.64 |
2,161 |
29,476 |
213,009 |
| PAKOLA STEVE | Chief Medical Officer |
Jul 01 '26 |
Option Exercise |
7.86 |
36,725 |
288,658 |
249,734 |
| PAKOLA STEVE | Chief Medical Officer |
Jul 01 '26 |
Sale |
12.86 |
36,725 |
472,284 |
213,009 |
| PAKOLA STEVE | Chief Medical Officer |
Jun 29 '26 |
Sale |
11.04 |
19,608 |
216,472 |
213,009 |
0.05%
0.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):